机译:PI3K途径抑制剂在胶质母细胞瘤中的临床研究进展
Center For Neuro-Oncology, Dana-Farber Cancer Institute, SW430D, 450 Brookline Ave., Boston, MA 02215 Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital Harvard Medical School, Boston, MA;
Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital Harvard Medical School, Boston, MA;
Harvard Medical School, Boston, MA Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center;
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute Department of Pathology, Brigham and Women's Hospital Children's Hospital Boston Harvard Medical School, Boston, MA;
Division of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX;
AKT; glioblastoma; GBM; mtor; PI3K;
机译:PI3K抑制剂用于多形性胶质母细胞瘤的最新进展:当前的临床前和临床开发
机译:受体酪氨酸激酶途径中的多个病变决定了胶质母细胞瘤对pan-ERBB抑制剂PF-00299804和PI3K / mTOR双重抑制剂PF-05212384的反应
机译:从长凳到床侧:PI3K通路抑制剂在临床开发中
机译:PI3K抑制剂临床发展挑战
机译:BEZ235,PI3K / mTOR抑制剂和依维莫司,mTOR抑制剂的新型组合的临床药代动力学:I期临床研究和非临床机制评估
机译:PI3K途径抑制剂在胶质母细胞瘤中的临床研究进展
机译:PI3K抑制剂用于多形性胶质母细胞瘤的最新进展:当前的临床前和临床开发